This trial is active, not recruiting.

Condition pulmonary arterial hypertension
Treatment ftha, fdg pet imaging.
Sponsor Ottawa Heart Institute Research Corporation
Collaborator Heart and Stroke Foundation of Ontario
Start date January 2011
End date December 2015
Trial size 20 participants
Trial identifier NCT01572077, 2010539-01H


The purpose of this study is to evaluate patterns of metabolic activity in the heart of patients with pulmonary arterial hypertension(PAH). Patients with PAH are at risk of developing weakness or failure of the right side of the heart.It is possible that there is a relationship between the development of heart failure and the way the heart uses energy sources, such as sugar. This study is designed to evaluate the way the heart uses sugar uptake in patients with PAH using positron emission tomography(PET imaging)

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose basic science
This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease. Both groups will undergo FTHA/FDG PET imaging.
ftha, fdg pet imaging.
Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).

Primary Outcomes

Cardiopulmonary death OR clinical right heart failure hospitalization
time frame: 1year

Secondary Outcomes

Change in right ventricular size and function as measured by cardiac MRI, between baseline and 1 year.
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria:(PATIENTS) - Patients with diagnosis of Category 1 pulmonary arterial hypertension due to any of the following: idiopathic, familial, associated with connective tissue disease, HIV disease or anorexigen use. - All patients who will require a right heart catheterization for further clinical management and/or diagnosis. - Patients will be considered eligible if they have no significant coronary artery disease (stenosis > 70% in a proximal or mid major coronary artery) or moderate coronary artery disease (60-70%) with abnormal left ventricular function (EF<50%) - Patients will be considered eligible in the absence of current or recent evidence of right heart failure. - No previous hospital admission or requirements of intravenous diuretics for right heart failure within 6 months of enrolment. - No increase in oral diuretics to control fluid volume within 6 months prior to enrolment - No current symptoms and signs of fluid retention or right heart strain, including any of the following: development of new ascites or peripheral edema > = 2+, JVP >7 cm above the sternal angle or a right atrial pressure >14 mmHg at the time of right heart catheterization. - In addition, we will include a small cohort of up to 15 patients with PAH and current RHF. Exclusion Criteria: - Patients with known significant coronary artery disease(defined as known stenosis >70% in a proximal or mid major artery or moderate coronary artery disease (60-70%)in a coronary artery and associated left ventricular ejection fraction <50%. - Patients with diabetes mellitus who require the use of oral hypoglycemics and or insulin. - Implantable metal devices, incompatible with magnetic resonance imaging. - Other contraindications of magnetic resonance imaging. Normal Control Subjects: - Subjects will have no known cardiac or pulmonary disease. - Normal ventricular function and estimated pulmonary pressures on echocardiogram.

Additional Information

Official title Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension
Principal investigator Lisa M Mielniczuk, MD
Description PAH results in premature death as a result of right ventricular dysfunction. However, there are substantial differences among patients in their tendency to develop right heart failure. This study proposes to determine if right ventricular (RV) changes can predict the development of right heart failure in patients with PAH. In addition, the study aims to evaluate the relationship of right ventricular metabolism to other physiologic responses in PAH,including:pulmonary vascular resistance, serum BNP and changes in cardiac hypertrophy and function. In conjunction with hemodynamic measurements, biomarkers and cardiac magnetic resonance imaging (MRI); RV metabolism will be evaluated with (18F) FTHA and (18F)FDG cardiac PET imaging. A cohort of 20 age sex matched individuals will serve as normal controls. These subjects will have no known cardiac or pulmonary disease with normal ventricular function and estimates pulmonary pressures on echocardiogram.
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation.